Twenty-two patients received pergolide mesylate for Parkinson's disease for one year. Improvement was maximal at six months, but average functional scores were still better at 12 months than at pretreatment evaluation. On-off fluctuations were reduced in severity, and two of 18 patients experienced full resolution. Pergolide is an effective and safe ongoing medication for Parkinson's disease.
No takes yet. Share an insight, caveat, or question.
Goetz et al. (1983) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: